Core Viewpoint - Recent developments for Lifan Pharmaceutical (stock code: 003020) focus on product procurement progress and market performance, with three core products expected to enhance sales and market share through national procurement [1] Group 1: Recent Events - Product Procurement Selection: On February 10, 2026, Lifan Pharmaceutical announced that its three products—Nifedipine Controlled-Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Trimethoprim Sustained-Release Tablets—are proposed for selection in the national procurement program, which could significantly boost sales and market share [2] - New Drug Application Progress: On the same day, the application for the raw material drug Finerenone was accepted by the National Medical Products Administration, aimed at treating chronic kidney disease related to type 2 diabetes, currently under review [2] Group 2: Stock Performance - Stock Price Movement: Over the past week (February 5 to 11), the stock price fluctuated by 0.84%, with a high of 26.99 yuan on February 6 and a low of 26.22 yuan on February 9. The closing price on February 11 was 26.53 yuan, with a single-day increase of 0.53% and a trading volume of 30.08 million yuan [3] - Capital Flow Situation: On February 11, there was a net outflow of 1.7835 million yuan from institutional investors, while retail investors showed a net inflow, indicating overall stable liquidity [3] Group 3: Sector Performance - Sector Comparison: During the same period, the pharmaceutical and biotechnology sector declined by 0.50%, while Lifan Pharmaceutical's stock performance was slightly better than the sector average [4] Group 4: Institutional Insights - Strategic Transformation Analysis: On February 6, 2026, Morningstar Research noted that Lifan Pharmaceutical is focusing on high-barrier areas such as osmotic pump controlled-release technology and narcotic drugs, with core products like Methylphenidate Hydrochloride Sustained-Release Tablets already on the market. However, short-term performance may experience fluctuations, necessitating attention to new drug volume and balancing R&D investments [5]

Group 1 - SMIC reported a net profit of 1.22 billion yuan for Q4 2025, representing a year-on-year increase of 23.2% [22][23] - The company achieved an operating revenue of 17.81 billion yuan, up 11.9% year-on-year [23] - The growth in performance is attributed to increased wafer sales volume, higher capacity utilization, and changes in product mix [23] Group 2 - Ge Wei Dong subscribed to a private placement of Jianghuai Automobile, investing approximately 1 billion yuan for 20.05 million shares at a price of 49.88 yuan per share [2] - Jianghuai Automobile raised a total of about 3.5 billion yuan through this issuance [2] Group 3 - Jia Mei Packaging announced that it may apply for a trading suspension again if its stock price experiences further abnormal increases, following a 567.11% price increase from December 17, 2025, to February 10, 2026 [3] - The company has been under close monitoring by the Shenzhen Stock Exchange due to significant price fluctuations [3] Group 4 - Lifan Pharmaceutical participated in a national centralized procurement process and expects to be selected for three products, which generated a total sales revenue of 14 million yuan in the first three quarters of 2025, accounting for 12.98% of its total revenue [5] Group 5 - ST Xuefa's related party, Xuesong Holdings, and its actual controller Zhang Jin were involved in a public fundraising fraud case, but the company stated that the case would not significantly impact its daily operations [6] Group 6 - Chu Tian Long plans to raise up to 760 million yuan through a private placement to fund projects related to innovative application security products and digital operations [7] Group 7 - Dong A Ejiao intends to invest 1.485 billion yuan in a health consumer goods industrial park project, focusing on the production of health food and related logistics [12] Group 8 - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium subsidiary due to reduced demand, but it is expected to have no significant impact on the company's operations [16] Group 9 - China Railway Construction recently won 10 major projects with a total value of 45.142 billion yuan, which represents 4.23% of its audited revenue for 2024 [21] Group 10 - New City Holdings reported a contract sales amount of approximately 714 million yuan in January 2026, a decrease of 29.79% year-on-year [27]

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]